0001209191-18-057255.txt : 20181105 0001209191-18-057255.hdr.sgml : 20181105 20181105172907 ACCESSION NUMBER: 0001209191-18-057255 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181102 FILED AS OF DATE: 20181105 DATE AS OF CHANGE: 20181105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hamel Lawrence G CENTRAL INDEX KEY: 0001511368 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35068 FILM NUMBER: 181160891 MAIL ADDRESS: STREET 1: C/O ACELRX PHARMACEUTICALS INC. STREET 2: 575 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001427925 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-216-3500 MAIL ADDRESS: STREET 1: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-02 0 0001427925 ACELRX PHARMACEUTICALS INC ACRX 0001511368 Hamel Lawrence G C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 0 1 0 0 Chief Development Officer Common Stock 2018-11-02 4 A 0 5000 2.225 A 34795 I By the Hamel Revocable Living Trust Common Stock 2018-11-02 4 D 0 5000 5.00 D 29795 I By the Hamel Revocable Living Trust Common Stock 24371 D Stock Option (Right to Buy) 2.225 2018-11-02 4 A 0 26125 0.00 A 2018-11-02 2028-11-02 Common Stock 26125 26125 D Stock Option (Right to Buy) 2.225 2018-11-02 4 D 0 5000 0.00 D 2018-11-02 2028-11-02 Common Stock 5000 21125 D Shares sold pursuant to a 10b5-1 plan. On April 7, 2018, the reporting person was granted an option to purchase 52,250 shares of common stock. The option vests in two equal annual installments based on Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019; and the remaining 50% of the award shall vest on the one-year anniversary of the date of such FDA approval, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 26,125 shares. /s/ Martha Adler, Attorney-In-Fact 2018-11-05